2023-503404-89-00RecruitingPhase 1
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Aug 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 8 Jul 2024
- Start date
- 8 Dec 2021
- Lead sponsor
- Genentech Inc.
- Diseases
- Multiple myeloma
- EU CT number
- 2023-503404-89-00
- EudraCT number
- 2021-002307-36
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 45
- 6 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (6)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Ziekenhuis Gent | Gent | Belgium | Recruiting |
| UZ Brussel | Jette | Belgium | Recruiting |
| Evangelismos S A | Athens | Greece | Recruiting |
| Alexandra Hospital | Athens | Greece | Recruiting |
| Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico | Bologna | Italy | Recruiting |
| Humanitas Mirasole S.p.A. | Rozzano | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.